Evenity (romosozumab; Amgen/UCB/Astellas) Drug Overview Report 2018 - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Drug Overview: Evenity” report has been added to ResearchAndMarkets.com’s offering.

Evenity (romosozumab; Amgen/UCB/Astellas) is a novel humanized monoclonal antibody therapy targeting the osteocyte-produced protein sclerostin, which inhibits bone formation in osteoblastic cells. As such, Evenity has an anabolic effect, and is being developed as a treatment for postmenopausal women with osteoporosis. Sclerostin is a key part of the negative feedback loop that acts to control the activity of osteoblastic cells. Knockout mice for SOST, the gene encoding sclerostin, show an increase in bone formation, resulting in greater bone mass and strength.

It is hypothesized that by inhibiting the activity of sclerostin as opposed to the activity of osteoclasts or osteoblasts directly, Evenity acts to uncouple the bone formation and bone resorption processes. This prevents the rebound increase in osteoclastic bone resorption that can be seen when parathyroid or parathyroid hormone-related peptides are used. This has been illustrated in both animal and human studies.

Key Topics Covered:


Drug Overview

Product Profiles

Evenity: Osteoporosis

List of Figures

Figure 1: Evenity for osteoporosis - SWOT analysis

Figure 2: Drug assessment summary of Evenity for osteoporosis

Figure 3: Drug assessment summary of Evenity for osteoporosis

List of Tables

Table 1: Evenity drug profile

Table 2: Evenity pivotal trial data in osteoporosis

Table 3: Evenity other late-phase trials in osteoporosis

For more information about this report visit https://www.researchandmarkets.com/research/nm3fbs/evenity?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006236/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs,Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 02:51 PM/DISC: 05/14/2018 02:51 PM


Update hourly